The DOI matches its Crossref record; the references it cites are not checked yet.
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial
Open accessAbstract
Background Metformin is increasingly being used during pregnancy, with potentially adverse long-term effects on children. We aimed to examine adiposity in children of women with type 2 diabetes from the Metformin in Women with Type 2 Diabetes in Pregnancy (MiTy) trial, with and without in-utero exposure to metformin, up to 24 months of age.Methods MiTy Kids is a follow-up study that included infants of women who participated in the MiTy randomised controlled trial, receiving either oral 1000 mg metformin twice daily or placebo. Caregivers and researchers remained masked to the type of medication (metformin or placebo) mothers received during their pregnancy. Anthropometric measurements, including weight, height, and skinfold thicknesses, were taken at 3, 6, 12, 18, and 24 months. At 24 months, linear regression was used to compare the BMI Z score and sum of skinfolds in the metformin versus placebo groups, adjusted for confounders. Fractional polynomials were used to assess growth trajectories. This study is registered with ClinicalTrials.gov, NCT01832181.Findings Of the 465 eligible children, 283 (61%) were included from 19 centres in Canada and Australia. At 24 months, there was no difference between groups in mean BMI Z score (0·84 [SD 1·52] with metformin vs 0·91 [1·38] with placebo; mean difference 0·07 [95% CI -0·31 to 0·45], p=0·72) or mean sum of skinfolds (23·0 mm [5·2] vs 23·8 mm [5·4]; mean difference 0·8 mm [-0·7 to 2·3], p=0·31). Metformin was not a predictor of BMI Z score at 24 months of age (mean difference -0·01 [95% CI -0·42 to 0·37], p=0·92). There was no overall difference in BMI trajectory but, in males, trajectories were significantly different by treatment (p=0·048); BMI in the metformin group was higher between 6 and 24 months. Children of women with type 2 diabetes were approximately 1 SD heavier than the WHO reference population.Interpretation Anthropometrics were similar in children exposed and those not exposed to metformin in utero; hence, overall, data are reassuring with regard to the use of metformin during pregnancy in women with type 2 diabetes and the long-term health of their children.Funding Canadian Institute for Health Research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, due to the potential for growth restriction or acidosis in the setting of placental insufficiency, metformin should not be used in pregnant people with hypertension or preeclampsia or those at risk for intrauterine growth restriction (90,95,96).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [90]
In the citing paper
“Follow-up of offspring from the Metformin in Women with Type 2 Diabetes in Pregnancy (MiTy Kids) trial showed no differences in anthropometrics of children at 24 months (90).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [90]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 32 · Cited by 61
Metadata
- Authors
- Feig, D. S., Sanchez, J. J., Murphy, K. E., Asztalos, E., Zinman, B., Simmons, D., Haqq, A. M., Fantus, I. G., Lipscombe, L., Armson, A., Barrett, J., Donovan, L., Karanicolas, P., Tobin, S., Mangoff, K., Klein, G., Jiang, Y., Tomlinson, G., Hamilton, J., Feig, D., Galper, A., Cleave, B., Strom, M., Poolman, K., Fong, D., Viguiliouk, E., Legault, L., Boutin, L., Ho, J., Virtanen, H., Zahedi, A., Szwiega, K., Coolen, J., Dias, R., Sellers, E., Fletcher, B., Bourrier, L., Haqq, A., Rylance, H., Hadjiyannakis, S., Courtney, J., McManus, R., Halperin, I., Miller, D., Coles, K., Simmons, D., Nema, J., Weisnagel, S., Dubé, M., Chanoine, J., Kwan, J., McIntyre, H., Laurie, J., Maguire, F., Soper, J., Bridger, T., Houlden, R., Breen, A., McLean, M., Duke, A., Hendon, S., & Sigmund, A.
- Affiliations
- Mount Sinai Hospital (CA)
- Sunnybrook Hospital (CA)
- Sunnybrook Health Science Centre (CA)
- Western Sydney University (AU)
- University of Alberta (CA)
- University of Toronto (CA)
- Dalhousie University (CA)
- University of Calgary (CA)
- University Health Network (CA)
- ORCID
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 11
- Issue
- 3
- Pages
- 191-202
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W4319067708
- Cited by
- 61
- References
- 32
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 18 · 2023: 14
- FWCI
- 19.03
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- TSpace (University of Toronto) (submittedVersion, cc-by-nc-nd)
- Funders
- Canadian Institutes of Health Research
- University of Guelph
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
- Keywords
- metformin, type 2 diabetes in pregnancy, maternal type 2 diabetes, prenatal drug exposure, childhood adiposity, BMI z-score, skinfold thickness, growth trajectories, infant anthropometry, long-term outcomes, offspring of diabetic mothers, sex differences in growth, gestational weight gain
- MeSH terms
- Canada, Child, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Infant, Metformin, Pregnancy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(23)00004-9
- The paper
- Feig, D. S., Sanchez, J. J., Murphy, K. E., Asztalos, E., Zinman, B., Simmons, D., Haqq, A. M., Fantus, I. G., Lipscombe, L., Armson, A., Barrett, J., Donovan, L., Karanicolas, P., Tobin, S., Mangoff, K., Klein, G., Jiang, Y., Tomlinson, G., Hamilton, J., . . . Sigmund, A. (2023). Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(23)00004-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.